Urgent Field Safety Notice

SBN-CPS-2020-001

RDS/core lab / Immunology
Version 8
December 2021

Elecsys CA 19-9: non-reproducible elevated results with certain reagent lots on cobas e 801 and e 402

Product Name	Elecsys CA 19-9
System	**cobas e** 801 **cobas e** 402
GMMI / Part No **Device Identifier**	Elecsys CA 19-9: 07027028 190
Production Identifier (Product name/Product code)	07027028 190: Lot 483123, 504743, 525510 and 568976
SW Version	n/a
Type of Action	Field Safety Corrective Action

Dear Valued Customer,

Description of Situation

As described in the former versions of SBN-CPS-2020-001, Elecsys CA 19-9 lots 416245, 464449 (both expired), 483123 and 504743 on **cobas e** 801 showed in internal investigations and/or customer complaints an increased rate of non-reproducible elevated results.

With the FSN-CPS-2020-001 version 8 we want to inform that the implemented corrective actions are currently in the evaluation phase and therefore the upcoming CA19-9 lot 568976 can be used on **cobas e** 801 and **cobas e** 402 analyzers only if the already described restrictions are applied.

The issue appears as follows:

Either result of multiple determinations is non-reproducibly elevated compared to the other results of the same sample aliquot. The issue has been observed with both plasma and serum samples.

The increased frequency of non-reproducible elevated results has been detected for reagent lots 416245, 483123 and 504743 which were released with restrictions in the former versions of FSN-CPS-2020-001.

The issue is reagent lot-specific and not related to the **cobas e** 801 instrument.

The issue can lead to non-reproducible elevated Elecsys CA 19-9 results and therefore may affect clinical interpretation.

Measures have been implemented to ensure consistent product quality of future lots. Until confirmation of the effectiveness of these measures, the upcoming CA 19-9 reagent lots still have to be released with restrictions: double determinations for all results ≥ 37 U/ml CA 19-9 must be applied as a precautionary measure.

For the time being, the restrictions as communicated previously for all affected lots still apply to allow for reliable detection of high flyers.

Elecsys CA 19-9: non-reproducible elevated res with certain reagent lots on cobas e 801 and e 402

Based on the current status of investigations, the interaction of (para)magnetic particles and proteins of the assay formulation being able to trigger the Elecsys ECLIA reaction may be specific for Elecsys CA 19-9. Beside this, contamination of the reagent during the filling process is still under investigation.
Recent internal investigations have been focusing on the visual detection of the high flyer events using high resolution microscopy. Although particle contamination could be confirmed in the measuring cell, the exact kinetics of the formation of highflyer aggregates during shelf-life, is still under investigation.
For the upcoming CA 19-9 lots, countermeasures to prevent contamination have been implemented. These comprise the quantitative detection of both protein aggregates and detection of (para-)magnetic particles. Production process has been further changed to deplete potential protein aggregates before filling and will be applied to the upcoming lots.

Due to residual medical risk described in the previous versions, customers using the Elecsys CA 19-9 lot 568976 must be informed using the FSN-CPS-2020-001 version 8.

Actions to be taken by Roche Diagnostics

Countermeasures to prevent contamination with (para-)magnetic particles were implemented in the filling process. Additional QC release criteria were defined and are implemented.

Until the proof of effectiveness is completed, upcoming lots have to be released with restrictions to ensure correctness of the results.

Actions to be taken by the customer/user

Customers using affected CA 19-9 lots on **cobas e** 801 and **cobas e** 402 are advised to apply the restrictions (double determinations) described below..

Based on the most recent complaints and our internal investigation, customers are advised to perform double determinations from the same tube for all results ≥ 37 U/ml CA 19-9 when using the reagent lots 483123, 504743, 525510 and 568976 in order to allow the detection of possible non-reproducible elevated results (high flyers). Customers can still use the entire ePack and there is no need to restrict the number of determinations to the first 200.

All reagent lots CA 19-9 (11776193 122) running on **cobas e** 411 / **e** 601 / **e** 602 can be used without restrictions.

The contamination of Elecsys CA 19-9 assay lots with (para-)magnetic particles is only one of the known causes of non-reproducible results. Although corrections have been made to prevent the contamination, other causes may still lead to a sporadic occurrence of non-reproducible results in the future.

Any specific questions raised by the users regarding review of results and possible re-testing should be addressed individually, considering all relevant clinical information.

General reminder regarding occurrence of high flyers:

Some of the most important aspects are:

- Correct and good sample preanalytic according to the specifications of the respective primary
- tube manufacturer (e.g. centrifugation time, speed, temperature)
- Avoidance or complete elimination of foam on or clots in the samples
- Regular and complete equipment maintenance according to the manufacturer's specifications
- Regular visual checks of e.g. the sample carriers to ensure correct positioning of the tubes on the analyzers.

Due to these alternative causes, flyers may continue to appear in the future at the frequency typical of the laboratory before the product problem.

Communication of this Field Safety Notice (if appropriate)

This notice must be passed on to all those who need to be aware within your organization where the devices have been distributed/supplied (if appropriate).

Please transfer this notice to other organizations/individuals on which this action has an impact.

Please maintain awareness of this notice and resulting action for an appropriate period to ensure the effectiveness of the corrective action.

The following statement is mandatory in FSNs for EEA countries but is not required for the rest of the World:

Include if applicable: The undersigned confirms that this notice has been notified to the appropriate Regulatory Agency.

We apologize for any inconvenience this may cause and hope for your understanding and your support.

<closing salutations>,

Contact Details

To be completed locally:

Name

Title

Company Name

Address

Tel. +xx-xxx-xxxx xxxx

Email name@roche.com